pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Dronabinol
drug · small molecule
save

dronabinol

Marketedupdated 3mo ago
by Vertanical GmbH🔗 ChEMBL
Approved
community read0 votes

🐶 often sniffed alongside

top 5
  • tagApproval92 co-mentions · 23 sources
  • drugMedchew Dronabinol47 co-mentions · 24 sources
  • tagSmall Molecule46 co-mentions · 23 sources
  • companySwinburne University of Technology1 co-mentions · 1 sources
  • tagPain1 co-mentions · 1 sources

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 4 approved and 32 investigational indications.

indications

investigational
Alzheimer's DiseaseParkinson's Disease

targets

Cannabinoid receptor 1

all catalysts(1)

phase 2 completion · 1
Apr 24, 2026
phase 2 completion
4mo ago
Swinburne University of Technology — dronabinol (Phase II Trial Completion)
dronabinol
→

Trials studying dronabinol

  • phase3RePOSA-Revealing the Efficacy of IHL-42X Use in Patients With OSAcompletedn=121
  • phase3To Evaluate the Efficacy, Safety, and Tolerability of Dronabinol Oral Solution for Agitation in Patients With Alzheimer's Diseasenot yet recruitingn=140
  • phase3Efficacy and Safety of Dronabinol in the Improvement of Chemotherapy-induced and Tumor-related Symptoms in Advanced Pancreatic Cancercompletedn=109
  • phase1Bioavailability, Bioequivalence and Tolerability of IHL-42X Compared to the Reference Drugscompletedn=125

Patent cliff

source: FDA Orange Book
first barrier falls
Aug 6, 2028
~2.0 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (4)

  • Aug 6, 2028compositionUS 102652932.0y
  • Aug 6, 2028compositionUS 112534722.0y
  • Aug 6, 2028compositionUS 82222922.0y
  • Aug 6, 2028compositionUS 93457712.0y

News(0)

no news has mentioned this drug yet

brand
Dronabinol
trade names
Dronabinol, Dronabinol component of ad-313, Dronabinol component of ad313, Dronabinol component of sci-110, Marinol, Syndros
generic
dronabinol
MOA
Cannabinoid CB1 receptor agonist
indication
Chronic Low Back Pain (CLBP)
phase
marketed
Data sources
ClinicalTrials.gov · OpenTargets
last refreshed 58m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?